All In Biotech

Drug Trial Radar · NCT07469891

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants With Polycythemia Vera and Myelofibrosis

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 29, 2026

Primary completion

Apr 2028

Study completion Apr 2028

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE\[s\]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).

Conditions

  • Polycythemia Vera (PV)
  • Myelofibrosis (MF)
  • Myeloproliferative Neoplasms (MPNs)
  • Post-Polycythemia Vera Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis
  • Primary Myelofibrosis (PMF)

Interventions

  • PRT12396Drug

    PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT) of PRT12396Time frame: Through cycle 1 (4 weeks)
  2. Incidence and severity of Adverse eventsTime frame: Through study completion, an average of 2 years
  3. Adverse Events Leading to Dose Modifications or DiscontinuationTime frame: Through study completion, an average of 2 years
  4. Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396Time frame: Through study completion, an average of 2 years

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • UCLA Ronald Reagan Medical Center

    Los Angeles, California · Recruiting

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • BRCR Global - Coral Springs

    Coral Springs, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • START Midwest, LLC

    Grand Rapids, Michigan · Recruiting

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office

    Philadelphia, Pennsylvania · Recruiting

  • Tennessee Oncology, PLLC - Investigational Drug Services

    Nashville, Tennessee · Recruiting

  • Tristar BMT

    Nashville, Tennessee · Recruiting

  • The University of Texas, MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Monash Health, Monash Medical Centre

    Clayton, Victoria, Australia · Recruiting

  • One Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)

    Nice, France · Recruiting

  • Saint-Louis Hospital

    Paris, France · Recruiting

  • Oncopole Claudius Regaud

    Toulouse, France · Recruiting

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy · Recruiting

  • Hospital Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Clínico Universitario de Valencia

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.